Research Article
Antimicrobial Resistance Patterns in Patients with Vaginal Discharge: A 2019-2022 Analysis at the National Health Laboratory in Eritrea
Table 3
Antimicrobial sensitivity of vaginal swab in National Health Laboratory (gram-negative species).
| | Isolate, (%) | Total () | value | | Citrobacter spp. () | E. coli () | Klebsiella spp. () | Other gram -ve () | Proteus spp. () |
| | Amikacin | I | 1 (14.3) | 15 (17.2) | 7 (36.8) | 1 (7.1) | 2 (33.3) | 26 (19.5) | 0.11 | | R | 2 (28.6) | 6 (6.9) | 2 (10.5) | 0 (0.0) | 1 (16.7) | 11 (8.3) | | S | 4 (57.1) | 66 (75.9) | 10 (52.6) | 13 (92.9) | 3 (50.0) | 96 (72.2) |
| | Cephalexin | I | 2 (28.6) | 39 (44.8) | 7 (36.8) | 2 (14.3) | 1 (16.7) | 51 (38.3) | 0.014 | | R | 5 (71.4) | 20 (23.0) | 4 (21.1) | 8 (57.1) | 4 (66.7) | 41 (30.8) | | S | 0 (0.0) | 28 (32.2) | 8 (42.1) | 4 (28.6) | 1 (16.7) | 41 (30.8) |
| | Ceftazidime | I | 0 (0.0) | 6 (6.9) | 2 (10.5) | 1 (7.1) | 0 (0.0) | 9 (6.8) | 0.039 | | R | 3 (42.9) | 7 (8.0) | 3 (15.8) | 4 (28.6) | 3 (50.0) | 20 (15.0) | | S | 4 (57.1) | 74 (85.1) | 14 (73.7) | 9 (64.3) | 3 (50.0) | 104 (78.2) |
| | Ceftriaxone | I | 2 (28.6) | 3 (3.4) | 0 (0.0) | 2 (14.3) | 0 (0.0) | 7 (5.3) | 0.060 | | R | 2 (28.6) | 12 (13.8) | 3 (15.8) | 2 (14.3) | 2 (33.3) | 21 (15.8) | | S | 3 (42.9) | 72 (82.8) | 16 (84.2) | 10 (71.4) | 4 (66.7) | 105 (78.9) |
| | Nalidixic acid | I | 1 (14.3) | 5 (5.7) | 4 (21.1) | 2 (14.3) | 1 (16.7) | 13 (9.8) | 0.253 | | R | 3 (42.9) | 20 (23.0) | 4 (21.1) | 2 (14.3) | 3 (50.0) | 32 (24.1) | | S | 3 (42.9) | 62 (71.3) | 11 (57.9) | 10 (71.4) | 2 (33.3) | 88 (66.2) |
| | Ampicillin | I | 1 (14.3) | 9 (10.3) | 3 (15.8) | 1 (7.1) | 0 (0.0) | 14 (10.1) | 0.85 | | R | 5 (71.4) | 58 (66.7) | 15 (78.9) | 11 (78.6) | 11 (78.6) | 100 (71.9) | | S | 1 (14.3) | 20 (23.0) | 1 (5.3) | 2 (14.3) | 1 (16.7) | 25 (18) |
| | Chloramphenicol | I | 0 (0.0) | 1 (1.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.8) | 0.01 | | R | 2 (28.6) | 7 (8.0) | 3 (15.8) | 3 (21.4) | 3 (50.0) | 18 (14) | | S | 5 (71.4) | 79 (90.8) | 16 (84.2) | 11 (78.6) | 3 (50.0) | 114 (85.7) |
| | Ciprofloxacin | I | 2 (28.6) | 5 (5.7) | 1 (5.3) | 0 (0.0) | 0 (0.0) | 8 (6) | 0.001 | | R | 1 (14.3) | 10 (11.5) | 2 (10.5) | 2 (14.3) | 3 (50.0) | 18 (14) | | S | 4 (57.1) | 72 (82.8) | 16 (84.2) | 12 (85.7) | 3 (50.0) | 107 (80.5) |
| | Trimethoprim-sulfamethoxazole | I | 1 (14.3) | 2 (2.3) | 2 (10.5) | 1 (7.1) | 0 (0.0) | 6 (4.5) | 0.225 | | R | 2 (28.6) | 43 (49.4) | 7 (36.8) | 4 (28.6) | 5 (83.3) | 61 (46) | | S | 4 (57.1) | 42 (48.3) | 10 (52.6) | 9 (64.3) | 1 (16.7) | 66 (49.6) |
| | Gentamicin | I | 1 (14.3) | 13 (14.9) | 4 (21.1) | 1 (7.1) | 2 (33.3) | 21 (15.8) | 0.001 | | R | 3 (42.9) | 20 (23.0) | 4 (21.1) | 1 (7.1) | 3 (50.0) | 31 (23) | | S | 3 (42.9) | 54 (62.1) | 11 (57.9) | 12 (85.7) | 1 (16.7) | 81 (60.9) |
| | Nitrofurantoin | I | 1 (14.3) | 6 (6.9) | 1 (5.3) | 4 (28.6) | 1 (16.7) | 13 (9.8) | 0.001 | | R | 0 (0.0) | 8 (9.2) | 9 (47.4) | 4 (28.6) | 4 (66.7) | 25 (19) | | S | 6 (85.7) | 73 (83.9) | 9 (47.4) | 6 (42.9) | 1 (16.7) | 95 (71.4) |
| | Tetracycline | I | 1 (14.3) | 3 (3.4) | 0 (0.0) | 1 (7.1) | 0 (0.0) | 5 (3.8) | 0.328 | | R | 3 (42.9) | 45 (51.7) | 9 (47.4) | 6 (42.9) | 6 (100.0) | 69 (51.9) | | S | 3 (42.9) | 39 (44.8) | 10 (52.6) | 7 (50.0) | 0 (0.0) | 59 (44.4) |
|
|
I: intermediate; R: resistant: S: sensitive.
|
